Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Cogent Inc. > Profile

Cogent Inc. (COGT)

This company is not actively trading or the ticker does belong to another company in our database now. The symbol (COGT) is currently associated with the following stock: Cogent Biosciences Inc. (COGT)
Sector: Services-Computer Integrated Systems Design

Insider Roster

Show All Insiders (14)
Hedge Fund Holdings
Filing Period:
No. Hedge Fund Shares Value Activity % Port
1.
Highbridge Capital Management

Glenn Russell Dubin

 0 $0 0%
Insider Trading: Sales See All
Insider Price Amount Total Value Remaining Holdings Date Form 4
Thornton
 $10.50 5,000 $52,500.00 4,000 2010-10-08 Filing
Hsieh
 $10.50 1,860,436 $19,534,578.00 0 2010-10-08 Filing
Hsieh
 $10.50 1,860,436 $19,534,578.00 0 2010-10-08 Filing
Hsieh
 $10.50 5,250,000 $55,125,000.00 0 2010-10-08 Filing
Hsieh
 $10.50 10,139,128 $106,460,844.00 0 2010-10-08 Filing
News See All
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD)

Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD)

On January 26, 2026, Cogent Biosciences, Inc. (NASDAQ:COGT) announced a major milestone, receiving a Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration.

Keep Reading →

February 2nd, 2026 - News

11 Best Performing Stocks in the Last 12 Months

11 Best Performing Stocks in the Last 12 Months

The year 2025 was not just another year but a period marked by sharp shifts in technology, geopolitics, and trade policy, often driving markets in surprising ways, according to Reuters' year-end report...

Keep Reading →

January 31st, 2026 - Hedge Funds News

H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT)

H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT)

Based on a research note dated January 6, 2026, The Fly reported that H.C. Wainwright reaffirmed a Buy rating and lifted its price target for Cogent Biosciences, Inc. (NASDAQ:COGT) from $50 to $52.

Keep Reading →

January 11th, 2026 - News

20 Best Performing Stocks in 2025

20 Best Performing Stocks in 2025

Reuters reported on January 1, 2026, that U.S.

Keep Reading →

January 9th, 2026 - Hedge Funds News

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best emerging technology stocks to invest in.

Keep Reading →

December 28th, 2025 - News

12 Best Emerging Technology Stocks to Invest In

12 Best Emerging Technology Stocks to Invest In

On December 24, Kevin Simpson of Capital Wealth Planning joined 'Closing Bell' on CNBC to talk about AI tailwinds and the diverging tech picture.

Keep Reading →

December 26th, 2025 - Hedge Funds News

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So

Cogent Biosciences Inc. (NASDAQ:COGT) is among the hottest SMID-cap stocks so far in 2025. On November 13, H.C.

Keep Reading →

November 23rd, 2025 - News

10 Hottest SMID-Cap Stocks So Far In 2025

10 Hottest SMID-Cap Stocks So Far In 2025

SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.

Keep Reading →

November 22nd, 2025 - Hedge Funds News

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress

Cogent Biosciences skyrocketed by 126.3 percent week-on-week, as investor sentiment was boosted by the promising results of its last clinical trial that tested the efficacy of its drug candidate for a...

Keep Reading →

November 16th, 2025 - News

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial

Cogent Biosciences soared to a new seven-year high on Monday, as investors cheered promising results of the last clinical trial phase that tested the efficacy of its drug candidate for a type of stomach...

Keep Reading →

November 11th, 2025 - News

Click here to See All News
Insider Monkey Quarterly Strategy
+498.7% Insider Monkey Quarterly Strategy
+195% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
400%
200%
0%

Returns since its inception in May 2014 (through February 18th, 2026)

Subscribe Now

30 day money back guarantee. Cancel anytime.